Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis

BACKGROUND & AIMS: Insulin resistance and lipotoxicity are pathognomonic in non-alcoholic steatohepatitis (NASH). Glucagon-like peptide-1 (GLP-1) analogues are licensed for type 2 diabetes, but no prospective experimental data exists in NASH. This study determined the effect of a long-acting GLP...

Descripción completa

Detalles Bibliográficos
Autores principales: Armstrong, Matthew J., Hull, Diana, Guo, Kathy, Barton, Darren, Hazlehurst, Jonathan M., Gathercole, Laura L., Nasiri, Maryam, Yu, Jinglei, Gough, Stephen C., Newsome, Philip N., Tomlinson, Jeremy W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4713865/
https://www.ncbi.nlm.nih.gov/pubmed/26394161
http://dx.doi.org/10.1016/j.jhep.2015.08.038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4713865/
https://www.ncbi.nlm.nih.gov/pubmed/26394161
http://dx.doi.org/10.1016/j.jhep.2015.08.038

Ejemplares similares